Klinik Araştırma

Investigation of the Sox-9 and Cited-1 Immune Activity in Placentas of Women with Placenta Accreta

Cilt: 5 Sayı: 2 15 Mayıs 2023
PDF İndir
EN

Investigation of the Sox-9 and Cited-1 Immune Activity in Placentas of Women with Placenta Accreta

Abstract

Aim: In this study, we investigated the immune activity of the Sox-9 and Cited-1 in women with placenta accreta. Material and Methods: 20 healthy and 20 placenta accreta were processed for routine histological tissue processing. Placentals samples were dissected and fixed in 10% formaldehyde solution. Samples were embedded in paraffin blocks. Clinical and biochemical parameters were recorded. Placental sections were cut from paraffin blocks and stained with Sox-9 and Cited-1 immunostaining. Results: In our study, control group showed negative Cited-1 expression in decidual cells, root villi and connective tissue areas in general. Placenta accreta group showed increased Cited-1 expression in degenerated decidual cells, fibroblastic cells and endothelium. In control group, Sox-9 expression was negative in the syncytial knots, in the vascular endothelial cells. In placenta accreta group, Sox-9 reaction was positive in the root villi, in the blood vessels, in the connective tissue. Conclusion: It was observed that the Sox-9 reaction was increased and inflammation was induced, depending on the differences in decidual cells, in the syncytial area and in the vascular endothelium in in placentas of women with placenta accreta. It is thought that Sox-9 signaling processes are being determined and Cited-1 may be stimulants that affect cell proliferation and angiogenesis regulation and affect placental development.

Keywords

Kaynakça

  1. Jansen CHJR, Kastelein AW, Kleinrouweler CE, et al. Development of placental abnormalities in location and anatomy. Acta Obstet Gynecol Scand. 2020;99:983-93.
  2. Oğlak SC, Ölmez F, Tunç Ş. Evaluation of Antepartum Factors for Predicting the Risk of Emergency Cesarean Delivery in Pregnancies complicated with placenta previa. Ochsner J. 2022;22:146-53.
  3. Papanikolaou IG, Domali E, Daskalakis G, et al. Abnormal placentation: Current evidence and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2018;228:98-105.
  4. Burton GJ, Jauniaux E. What is the placenta? Am J Obstet Gynecol. 2015; 13:6.e1,6-8.
  5. Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis Markers. 2018;2018:1507674.
  6. Bailit JL, Grobman WA, Rice MM, et al. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015;125:683-9.
  7. Ozkose ZG, Oglak SC, Behram M, et al. Maternal Serum Cripto-1 Levels in Pregnancies Complicated with Placenta Previa and Placenta Accreta Spectrum (PAS). J Coll Physicians Surg Pak. 2022;32:1570-75.
  8. Aşır F, Nergiz Y, Pala A. Vitamin E protected the mouse adrenal gland against immobilization stress. Pol J Vet Sci. 2022;25:447-54.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Tıp Bilimleri

Bölüm

Klinik Araştırma

Erken Görünüm Tarihi

15 Mayıs 2023

Yayımlanma Tarihi

15 Mayıs 2023

Gönderilme Tarihi

24 Ocak 2023

Kabul Tarihi

28 Şubat 2023

Yayımlandığı Sayı

Yıl 2023 Cilt: 5 Sayı: 2

Kaynak Göster

AMA
1.Akalın S, Öcal E, Deveci E. Investigation of the Sox-9 and Cited-1 Immune Activity in Placentas of Women with Placenta Accreta. Med Records. 2023;5(2):332-6. doi:10.37990/medr.1239182

Cited By